Immunotherapy Drugs Market Growth, Size, Trends Analysis- By Type of Drug, By Therapy Area, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Immunotherapy Drugs Market Introduction and Overview

SPER Market Research in the publication titled "Global Immunotherapy Drugs Market Size - By Drug Type, Therapy Area, and End User: Regional Outlook, Competitive Strategies, and Segment Forecast to 2033," the global market for immunotherapy drugs is projected to reach USD 674.09 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.75%.

Immunotherapy is a type of medical treatment that stimulates the immune system to attack diseases such as cancer. Immunotherapy drugs aim to improve or modify the immune system's response to aberrant cells. Immunotherapy is used to treat cancers like melanoma, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma.

The COVID-19 outbreak has had a substantial influence on the global immunotherapy medication industry. The outbreak has caused delays in clinical trials and research, as well as disruptions in industrial and supply chain operations. The outbreak, however, has sparked interest in the use of immunotherapy drugs to treat Covid-19, resulting in increased funding and research in this field.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Type of Drug, By Therapy Area, By End User.

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Companies Covered Abbott, PerkinElmer Inc, Illumina, Inc, QIAGEN, F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca, Pfizer Inc, Sanofi, Johnson & Johnson Services, Inc, AbbVie Inc, Allergan.

Immunotherapy Drugs Market Segmentation:

By Type of Drug: Based on the Type of Drug, Global Immunotherapy Drugs Market is segmented as; Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha and Beta, Interleukins and Other Drugs.

By Therapy Area: Based on the Therapy Area, Global Immunotherapy Drugs Market is segmented as; Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases and Other Therapy Areas.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Product Code: PHAR2416

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Immunotherapy Drugs Market.

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Immunotherapy Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Immunotherapy Drugs Market

7. Global Immunotherapy Drugs Market, By Type of Drug USD Million) 2020-2033

7.1. Global Immunotherapy Drugs Market Size, Share and Forecast, By Type of Drug, 2020-2026
7.2. Global Immunotherapy Drugs Market Size, Share and Forecast, By Type of Drug, 2027-2033
7.3. Monoclonal Antibodies
7.4. Adult Vaccines
7.5. Checkpoint Inhibitors
7.6. Interferons Alpha and Beta
7.7. Interleukins
7.8. Other Drugs

8. Global Immunotherapy Drugs Market, By Therapy Area (USD Million) 2020-2033

8.1. Global Immunotherapy Drugs Market Size, Share and Forecast, By Therapy Area, 2020-2026
8.2. Global Immunotherapy Drugs Market Size, Share and Forecast, By Therapy Area, 2027-2033
8.3. Cancer
8.4. Autoimmune and Inflammatory Diseases
8.5. Infectious Diseases
8.6. Other Therapy Areas

9. Global Immunotherapy Drugs Market, By End User (USD Million) 2020-2033

9.1. Global Immunotherapy Drugs Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global Immunotherapy Drugs Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Clinics
9.5. Other End Users

10. Global Immunotherapy Drugs Market Forecast, 2020-2033 (USD Million)

10.1. Global Immunotherapy Drugs Market Size and Market Share

11. Global Immunotherapy Drugs Market, By Region, 2020-2033 (USD Million)

11.1. Global Immunotherapy Drugs Market Size and Market Share By Region (2020-2026)
11.2. Global Immunotherapy Drugs Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
- 11.3.1. Australia
- 11.3.2. China
- 11.3.3. India
- 11.3.4. Japan
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
11.4. Europe
- 11.4.1. France
- 11.4.2. Germany
- 11.4.3. Italy
- 11.4.4. Spain
- 11.4.5. United Kingdom
- 11.4.6. Rest of Europe
11.5. Middle East and Africa
- 11.5.1. Kingdom of Saudi Arabia
- 11.5.2. United Arab Emirates
- 11.5.3. Qatar
- 11.5.4. South Africa
- 11.5.5. Egypt
- 11.5.6. Morocco
- 11.5.7. Nigeria
- 11.5.8. Rest of Middle-East and Africa
11.6. North America
- 11.6.1. Canada
- 11.6.2. Mexico
- 11.6.3. United States
11.7. Latin America
- 11.7.1. Argentina
- 11.7.2. Brazil
- 11.7.3. Rest of Latin America

12. Company Profile

12.1. Abbott
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. PerkinElmer Inc
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Illumina, Inc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. QIAGEN
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. F. Hoffmann-La Roche Ltd
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Novartis AG
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. AstraZeneca
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Pfizer Inc
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Sanofi
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Johnson & Johnson Services, Inc
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. AbbVie Inc
- 12.11.1. Company details
- 12.11.2. Financial outlook
- 12.11.3. Product summary
- 12.11.4. Recent developments
12.12. Allergan
- 12.12.1. Company details
- 12.12.2. Financial outlook
- 12.12.3. Product summary
- 12.12.4. Recent developments
12.13. Others